However, the ADA now recommends, as first-line therapy, SGLT-2 inhibitors and/or GLP-1 agonists in patients with CVD (or high risk of CVD) or chronic kidney disease, and GLP-1 agonists to achieve weight management goals [83]. This evidence concerns the gene SLC5A2 and chronic kidney disease.